PressOctober 5, 2022 Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
PressOctober 5, 2022 PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
PressOctober 5, 2022 Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
PressOctober 4, 2022 Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
PressOctober 4, 2022 PSYC Corporation Discusses Significance of Expansion into Cannabis and Precious Metals Sectors with The Stock Day Podcast
PressOctober 4, 2022 Irwin Naturals Agrees to Add Idaho Clinic to Its National Chain of Psychedelic Mental-Health Clinics
PressOctober 4, 2022 MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
PressOctober 4, 2022 PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA
PressOctober 4, 2022 KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers
PressOctober 4, 2022 Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares
PressOctober 4, 2022 PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
PressOctober 4, 2022 Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin
PressOctober 3, 2022 Revitalist Non-Profit, “Community Change Foundation”, Receives $1M Grant to Address Adolescent Mental Health and School Violence
PressOctober 3, 2022 Silo Pharma Initiates FDA Pre-Investigational New Drug Package for Time-Released Ketamine Technology
PressOctober 1, 2022 Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
PressOctober 1, 2022 Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option
PressSeptember 30, 2022 MindMed Board is Trippin’: Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
PressSeptember 30, 2022 Supermind Platforms, Inc Acquires Psychedelics.com and Closes Pre-Seed Financing
PressSeptember 30, 2022 Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting
